The Cardiovascular & Respiratory Pharmacology Affinity Group aims to provide a supportive, inclusive forum for Society members with an interest in all aspects of cardiovascular and respiratory pharmacology.
This encompasses the whole spectrum of pharmacology, so will be of relevance to members interested in medicinal chemistry, cellular, tissue and whole organism responses, and those involved in human clinical studies. The aim is to provide an overarching forum for pharmacological aspects of normal physiological responses through to studies in different disease states, including the effect of existing drugs as well as novel interventions. Those who are already a member of other Society Affinity Groups, who may also have cardiovascular or respiratory interests, are also encouraged to join the Cardiovascular & Respiratory Pharmacology Affinity Group.
Cardiovascular and respiratory research has always been very strongly represented at British Pharmacology Society meetings, with many oral and poster communications and symposia. Pharmacology 2017 will be no exception;
- In partnership with the British Society for Cardiovascular Research, we are presenting a symposium: ‘Cardiovascular pleiotropy, fact or fantasy?’ where we will explore cardiovascular benefits of drugs used for diabetes as well as statins and anti-platelet targets
- We will also explore coagulation and thrombosis in disease states in the symposium: ‘Clearing the blockage: bench to bedside approaches for clearing inflammation-induced thrombosis’
- A third symposium will concentrate on hypertension, with particular emphasis on the immune system: ‘Immune targets in hypertension’
Inflammation and cytokine-based therapies are also explored in other symposia, aligned with the Integrated Systems Pharmacology Affinity Group, with specific emphasis on cardiovascular disease and acute and chronic lung inflammation (‘Cytokine-based therapies in inflammatory diseases’).
Over the past year, events organised by the Cardiovascular & Respiratory Pharmacology Affinity Group have included a Society Focused Meeting at Magdalen College, University of Oxford last September on ‘Pharmacological aspects of microvascular cell-cell signalling and CVS disease’, which attracted delegates and speakers from across Europe, and as far away as Australia and the USA.
Overall, we welcome you to the Cardiovascular & Respiratory Pharmacology Affinity Group, and if you are not already a member, we encourage you to sign up on the Society's website. We look forward to welcoming you to Pharmacology 2017 and seeing you in London. Finally, we are always keen to hear your thoughts and ideas about Focused Meetings or events you would like us to organise, and suggestions for symposia we should include in future Society meetings.
More from Affinity groups
Comments
If you are a British Pharmacological Society member, please
sign in to post comments.